Abstract:Purpose: The aberrantly upregulated Friend leukemia virus integration 1 (FLI1) is closely correlated with the malignant phenotype of small cell lung cancer (SCLC). It is interesting to note that the CRISPR gene knockout by Cas9 gRNAs that target the FLI1 coding region and the posttranscriptional knockdown by shRNAs that target the 3 0 region of FLI1 mRNA yielded distinct antimetastasis effects in SCLC cells. This study attempts to examine if FLI1 exonic circular RNAs (FECR) function as a new malignant driver that determines the metastatic phenotype in SCLC. Experimental Design: The clinical relevance of FECRs was examined in 56 primary SCLC tissues and 50 non-small cell lung cancer (NSCLC) tissues. The prognostic value of FECRs was examined by measuring serum exosomal FECRs in a longitudinal cohort of patients with SCLC. The oncogenic activity of FECRs was investigated in both SCLC cell lines and animal xenograft studies. Finally, we explored the molecular mechanisms underlying these noncoding RNAs as a malignant driver. Results: Therapeutic comparison of CRISPR Cas9 knockout and shRNA knockdown of FLI1 identified FECRs as a new noncanonical malignant driver in SCLC. Using RNA FISH and quantitative PCR, we found that FECR1 (exons 4-2-3) and FECR2 (exons 5-2-3-4) were aberrantly upregulated in SCLC tissues (P < 0.0001), and was positively associated with lymph node metastasis (P < 0.01). Notably, serum exosomal FECR1 was associated with poor survival (P = 0.038) and clinical response to chemotherapy. Silencing of FECRs significantly inhibited the migration in two highly aggressive SCLC cell lines and reduced tumor metastasis in vivo. Mechanistically, we uncovered that FECRs sequestered and subsequently inactivated tumor suppressor miR584-3p, leading to the activation of the Rho Associated Coiled-Coil Containing Protein Kinase 1 gene (ROCK1). Conclusions: This study identifies FLI1 exonic circular RNAs as a new oncogenic driver that promotes tumor metastasis through the miR584-ROCK1 pathway. Importantly, serum exosomal FECR1 may serve as a promising biomarker to track disease progression of SCLC.

The Rna Binding Protein Fxr1 Is A New Driver In The 3q26-29 Amplicon And Predicts Poor Prognosis In Human Cancers

Sideroflexin1 As a Novel Tumor Marker Independently Predicts Survival in Lung Adenocarcinoma

Abstract 3043: FXR1 Promotes Lung Cancer Cell Growth by Regulating Oncogenic Targets in the 3Q26-3Q28 Amplicon

FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis

Comprehensive Bioinformatics Analysis of FXR1 Across Pan-Cancer: Unraveling Its Diagnostic, Prognostic, and Immunological Significance

The multifaceted role of Fragile X-Related Protein 1 (FXR1) in cellular processes: an updated review on cancer and clinical applications

FXR1 associates with and degrades PDZK1IP1 and ATOH8 mRNAs and promotes esophageal cancer progression

Farnesoid X Receptor, a Novel Proto-Oncogene in Non-Small Cell Lung Cancer, Promotes Tumor Growth Via Directly Transactivating CCND1

FXR1 can bind with the CFIm25/CFIm68 complex and promote the progression of urothelial carcinoma of the bladder by stabilizing TRAF1 mRNA

FXR1 is elevated in colorectal cancer and acts as an oncogene

PRMT5-mediated arginine methylation of FXR1 is essential for RNA binding in cancer cells

Fascin actin-bundling protein 1 regulates non-small cell lung cancer progression by influencing the transcription and splicing of tumorigenesis-related genes

Global Gene Expression Profiling Reveals a Suppressed Immune Response Pathway Associated with 3q Amplification in Squamous Carcinoma of the Lung

RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC

Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

SFPQ promotes RAS-mutant cancer cell growth by modulating 5'-UTR mediated translational control of CK1α

FLI1 Exonic Circular RNAs As a Novel Oncogenic Driver to Promote Tumor Metastasis in Small Cell Lung Cancer

Non-coding RNA-mediated high expression of SFXN3 as a prognostic biomarker associated with paclitaxel resistance and immunosuppressive microenvironment in head and neck cancer

The Role of FGFR1 Gene Amplification As a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.

Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining.

Upregulation of Long Non-Coding RNA RAB1A-2 Induces FGF1 Expression Worsening Lung Cancer Prognosis